Multimodality Magnetic Resonance Imaging of Prostate Cancer

Engelbrecht, Marc R.; Puech, Philippe; Colin, P.; Akın, Oğuz; Lemaître, L.; Villers, Arnauld

doi:10.1089/end.2009.0597

Cited by 31 publications

(22 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…That approach, which may identify some patients with higher risk disease, has not been embraced by most advocates of active surveillance and does not appear necessary in most patients. Dynamic contrastenhanced (dce) magnetic resonance imaging (mri) is emerging as a means to further assess extent of disease in patients with, for example, borderline psa kinetics and minimal disease on biopsy 20 .…”

Section: Are the Clinical Tools Available To Make Activementioning

confidence: 99%

Active Surveillance for Prostate Cancer: Patient Selection and Management

Klotz

2010

Current Oncology

View full text Add to dashboard Cite

Screening for prostate cancer using prostate-specific antigen (psa) has been appealing. However, the significant associated decline in prostate cancer mortality comes at the cost of a very high rate of diagnosis, and many patients with indolent, non-life-threatening cancer are exposed to the risk of significant side effects from radical treatment. Most men with favourablerisk prostate cancer are not destined to die of their disease, even in the absence of treatment. The challenge is to identify the subset that harbour more aggressive disease early enough that curative therapy is still a possibility, thereby allowing the others to enjoy improved quality of life, free from the side effects of treatment. This article reviews current research into active surveillance in favourable-risk disease and some of the issues that arise when prostate cancer is monitored rather than being treated immediately.

show abstract

Section: Are the Clinical Tools Available To Make Activementioning

confidence: 99%

Active Surveillance for Prostate Cancer: Patient Selection and Management

Klotz

2010

Current Oncology

View full text Add to dashboard Cite

show abstract

“…To improve prostate cancer detection, conventional T 2 WI is complemented by functional MR techniques such as DCE-MRI, DWI, and MRS. [8][9][10] The present study investigated the use of T 2 WI and DCE-MRI at 3.0T to differentiate cancerous prostate tissue from noncancerous tissue, and found that DCE-MRI was significantly more sensitive, accurate and had better NPV for cancer detection than T 2 WI. Specificity and PPV were not significantly different between DCE-MRI and T 2 WI, however.…”

Section: Discussionmentioning

confidence: 84%

“…6,7 Functional MR techniques (such as dynamic contrast-enhanced MRI [DCE-MRI], diffusion-weighted imaging [DWI], and magnetic resonance spectroscopy [MRS]) have been used to increase the diagnostic accuracy of MR in prostate cancer. [8][9][10] Dynamic contrast-enhanced MRI is useful in imaging tumour vascularization, vascular permeability and perfusion. 11 The method involves intravascular injection of contrast agents and imaging of their concentrations in blood and tissue over time.…”

Section: Introductionmentioning

confidence: 99%

The clinical value of dynamic contrast-enhanced magnetic resonance imaging at 3.0T to detect prostate cancer

Zhang

Quan

et al. 2014

J Int Med Res

View full text Add to dashboard Cite

Objective: To compare dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) and T 2 -weighted imaging (T 2 WI) at 3.0T for detection of prostate cancer. Methods: Patients with elevated prostate-specific antigen underwent T 2 WI and DCE-MRI prior to prostate needle biopsy. The sensitivity, specificity, accuracy, positive predictive value (PPV) and negative predictive value (NPV) of T 2 WI and DCE-MRI to diagnose prostate cancer were evaluated. The relationship between Gleason score and prostate cancer detection by DCE-MRI was evaluated. Results: Prostate adenocarcinoma was histopathologically confirmed in 44/75 patients. DCE-MRI had significantly higher sensitivity, accuracy and NPV than T 2 WI. The detection rate of prostate cancer by DCE-MRI was significantly better for tumours with Gleason score 7-9 than for those Gleason score 4-6. Conclusion: DCE-MRI at 3.0T can significantly improve prostate cancer detection using simple visual diagnostic criteria, compared with T 2 WI.

show abstract

“…24 The low-risk group contained patients with T1-T2a tumor, Gleason score <7, and PSA<10 ng/mL; intermediate-risk…”

Section: Study Design and Patient Populationmentioning

confidence: 99%

Correlation of Clinical Risk Factors with Diffusion-Weighted Magnetic Resonance Images in Prostate Cancer Patients Treated with Definitive Radiotherapy

Erbay¹

2015

UHOD

View full text Add to dashboard Cite

This study is aimed to correlate apparent diffusion coefficient (ADC) values and clinical T-stage, serum PSA, pathology Gleason scores. We also further analyzed whether ADC values could be used to appropriately define the risk groups. 135 biopsy-proven, radiotherapy-(RT)-treated, prostate cancer patients who underwent pre-RT DW-MRI and standard T2W pelvic MRI were included. ADC and normalized ADC (nADC) values were calculated from DW-MRI delivered a median 8.1 weeks after prostate biopsy. ADC values were correlated with clinical risk factor values by using Pearson correlation test. ADCs in low-, intermediate-, and high-risk patients were 0.873±0.122X10 -3 mm 2 /s, 0.763±0.124X10 -3 mm 2 /s, and 0.701±0.132X10 -3 mm 2 /s (p= 0.001), respectively. Patients with preRT PSA <10 ng/mL had significantly higher ADCs than patients with preRT PSA 10-20 ng/mL (p= 0.02) or >20 ng/mL (p< 0.001). Mean ADC for patients with Gleason score <7 was significantly higher than patients scoring 7 (p= 0.001) or >7 (p < 0.001). Clinical stage 20 ng/mL (p< 0.001) olan hastalara göre istatistiksel olarak anlamı derecede yüksek ADC değerlerine sahipti. Gleason Skoru <7 olan hastalar için ortalama ADC skoru, gleason 7 (p = 0.001) veya >7 (p < 0.001) olanlara göre anlamlı derecede yüksekti. Klinik evre 2b (p < 0.001) hastalara ...

show abstract

Multimodality Magnetic Resonance Imaging of Prostate Cancer

Cited by 31 publications

References 44 publications

Active Surveillance for Prostate Cancer: Patient Selection and Management

Active Surveillance for Prostate Cancer: Patient Selection and Management

The clinical value of dynamic contrast-enhanced magnetic resonance imaging at 3.0T to detect prostate cancer

Correlation of Clinical Risk Factors with Diffusion-Weighted Magnetic Resonance Images in Prostate Cancer Patients Treated with Definitive Radiotherapy

Contact Info

Product

Resources

About